Short Interest in Renovaro Inc. (NASDAQ:RENB) Increases By 30.7%

Renovaro Inc. (NASDAQ:RENB) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totalling 5,060,000 shares, a growth of 30.7% from the December 15th total of 3,870,000 shares. Based on an average trading volume of 1,030,000 shares, the days-to-cover ratio is presently 4.9 days. Approximately 6.6% of the shares of the stock are short sold.

Renovaro Stock Performance

Shares of NASDAQ RENB traded down $0.04 during midday trading on Friday, reaching $0.71. 624,909 shares of the company traded hands, compared to its average volume of 1,574,592. The stock’s 50-day simple moving average is $0.98 and its 200-day simple moving average is $0.85. Renovaro has a 12 month low of $0.40 and a 12 month high of $5.25. The firm has a market cap of $112.22 million, a PE ratio of -0.74 and a beta of 0.66.

Hedge Funds Weigh In On Renovaro

Institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its stake in Renovaro by 193.3% during the fourth quarter. SG Americas Securities LLC now owns 51,725 shares of the company’s stock worth $43,000 after buying an additional 34,090 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Renovaro by 347.6% in the third quarter. JPMorgan Chase & Co. now owns 93,010 shares of the company’s stock valued at $45,000 after acquiring an additional 72,230 shares during the last quarter. Barclays PLC grew its position in Renovaro by 315.7% during the 3rd quarter. Barclays PLC now owns 69,531 shares of the company’s stock worth $34,000 after acquiring an additional 52,804 shares during the last quarter. State Street Corp increased its holdings in Renovaro by 3.8% during the 3rd quarter. State Street Corp now owns 1,323,832 shares of the company’s stock valued at $640,000 after purchasing an additional 48,114 shares in the last quarter. Finally, Rhumbline Advisers bought a new position in Renovaro in the 2nd quarter valued at $79,000. 71.41% of the stock is owned by institutional investors.

Renovaro Company Profile

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.